Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas

[1]  Brian Walters,et al.  Cardiotoxicity of the cancer therapeutic agent imatinib mesylate , 2006, Nature Medicine.

[2]  Allan H Friedman,et al.  Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  G. Dresemann.  Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  A. Brandes,et al.  Adjuvant chemotherapy in the treatment of high grade gliomas. , 2005, Cancer treatment reviews.

[5]  M. Gilbert,et al.  Anaplastic astrocytoma: diagnosis, prognosis, and management. , 2004, Seminars in oncology.

[6]  M. J. van den Bent,et al.  Multicentre phase II study of imatinib mesylate in patients with recurrent glioblastoma: An EORTC: NDDG/BTG Intergroup Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Engelhard,et al.  Oligodendroglioma and anaplastic oligodendroglioma: clinical features, treatment, and prognosis. , 2003, Surgical neurology.

[8]  K. Hoang-Xuan,et al.  Primary brain tumours in adults , 2003, The Lancet.

[9]  L. Stewart,et al.  Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.

[10]  B. Scheithauer,et al.  A phase III study of radiation therapy plus carmustine with or without recombinant interferon‐α in the treatment of patients with newly diagnosed high‐grade glioma , 2001 .

[11]  R A Betensky,et al.  Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  M. Brada.  Pathology and Genetics of Tumours of the Nervous System , 2001, British Journal of Cancer.

[13]  D. Louis,et al.  Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. , 2000, Journal of neurosurgery.

[14]  B. Scheithauer,et al.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M J Gleason,et al.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[17]  L. Rorke,et al.  Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Graham.  Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.

[19]  V. Levin.  The place of hydroxyurea in the treatment of primary brain tumors. , 1992, Seminars in oncology.

[20]  Ron Brookmeyer,et al.  A Confidence Interval for the Median Survival Time , 1982 .

[21]  W. Wara,et al.  A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas. , 1979, Journal of neurosurgery.

[22]  L. D.,et al.  Brain tumors , 2005, Psychiatric Quarterly.

[23]  M. Prados,et al.  Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors. , 1998, International journal of radiation oncology, biology, physics.

[24]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .